⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 18, 2020Expert Opinion on Investigational DrugsOpen Access

Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges

Sander Lefere Lindsey Devisscher Frank Tacke

View Full Paper

Ask AI

Bookmark

Share

Abstract

In parallel to the obesity pandemic, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in adults worldwide [1]. Especially its inflammatory form, no...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lefere et al. (2020) studied this question.

synapsesocial.com/papers/6ab33b34274437374560da67 https://doi.org/10.1080/13543784.2020.1718106

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Designing for success in early phase haemophilia clinical trials: historical lessons and emerging principles for next generation therapeuticsExpert Opinion on Investigational Drugs · 2026
2Targeting the proteasome in Leishmania donovani : developments from preclinical to Phase I and ii trialsExpert Opinion on Investigational Drugs · 2026
3Zovegalisib for PIK3CA -driven vascular and lymphatic malformations: a drug evaluationExpert Opinion on Investigational Drugs · 2026
4Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancersExpert Opinion on Investigational Drugs · 2026
5Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcomaExpert Opinion on Investigational Drugs · 2026

Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral densityExpert Opinion on Investigational Drugs · 2026
Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural productsExpert Opinion on Investigational Drugs · 2026
Varespladib for snakebite envenomingExpert Opinion on Investigational Drugs · 2026
Up and coming early phase CAR T-cell therapy for treating relapsed or refractory large B-cell lymphomaExpert Opinion on Investigational Drugs · 2026
HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer?Expert Opinion on Investigational Drugs · 2026

More from Expert Opinion on Investigational Drugs

More from Charité - Universitätsmedizin Berlin

More from Ghent University

More from Ghent University Hospital